네바다의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 22개가 네바다 내 여러 지역에서 참여자를 모집하고 있습니다.
네바다의 도시
공식 연구 텍스트(영어)
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Renown Regional Medical Center, Reno
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07100080A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037), Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT06312137A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207), Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT07513376A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Renown Regional Medical Center, Reno
- Cancer Care Specialists, Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT07541170A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Renown Regional Medical Center, Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT06561386A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Renown Health Medical Oncology, Reno
- Renown Office of Clinical Research, Reno
- Renown Regional Medical Center, Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07144280A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Cancer Care Specialists, Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT06793215Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- OptumCare Cancer Care at Seven Hills, Henderson
- OptumCare Cancer Care at Charleston, Las Vegas
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06418204A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Comprehensive Cancer Centers of Nevada, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06119581Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134), Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT06170788Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Cancer Care Specialists, Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT07195695Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- OptumCare Nevada, Las Vegas
- Local Institution - 007-938A, Las Vegas
- Local Institution - 007-938B, Las Vegas
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT04613596Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06357533Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Renown Regional Medical Center, Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT06899126A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Renown Regional Medical Center /ID# 273535, Reno
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 22. 업데이트됨 · NCT06568939A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 110, Las Vegas
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT05914116Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #55, Las Vegas
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT05176483A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Reno
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06868277Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Research Site, Las Vegas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 26. 업데이트됨 · NCT06350097A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Comprehensive Cancer Centers of Nevada, Las Vegas
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT04389632Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- OptumCare Cancer Care at Charleston, Las Vegas
- OptumCare Cancer Care at Fort Apache, Las Vegas
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 3. 업데이트됨 · NCT05642572GEMINI-NSCLC: NSCLC Biomarker Study
- OptumCare Cancer Care, Las Vegas
- Hope Cancer Care of Nevada, Las Vegas
- Cancer Care Specialists Reno, Reno
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 2. 5. 업데이트됨 · NCT05236114ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.